TG Therapeutics, Inc.
TGTX
$29.45
$0.6752.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 30.96% | 33.54% | 40.80% | 39.53% | 1,341.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.96% | 33.54% | 40.80% | 39.53% | 1,341.63% |
| Cost of Revenue | 135.86% | 159.60% | 172.34% | 392.68% | 805.45% |
| Gross Profit | 22.77% | 24.83% | 32.34% | 27.44% | 1,411.50% |
| SG&A Expenses | 36.09% | 31.60% | 25.75% | 28.44% | 43.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.37% | 35.52% | 34.76% | 27.11% | 27.05% |
| Operating Income | -15.71% | 23.71% | 103.21% | 97.33% | 160.37% |
| Income Before Tax | -30.98% | 0.30% | 95.94% | 46.40% | 154.53% |
| Income Tax Expenses | 6,109.89% | 518.14% | 466.92% | -- | -- |
| Earnings from Continuing Operations | -36.82% | -4.97% | 84.52% | 44.55% | 154.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.82% | -4.97% | 84.52% | 44.55% | 154.47% |
| EBIT | -15.71% | 23.71% | 103.21% | 97.33% | 160.37% |
| EBITDA | -15.80% | 23.37% | 101.48% | 97.82% | 160.56% |
| EPS Basic | -38.32% | -6.17% | 100.50% | 51.41% | 152.95% |
| Normalized Basic EPS | -32.61% | -0.94% | 112.69% | 53.08% | 153.00% |
| EPS Diluted | -37.96% | 10.97% | 1,308.25% | 58.75% | 146.91% |
| Normalized Diluted EPS | -31.90% | 16.48% | 823.08% | 61.98% | 147.42% |
| Average Basic Shares Outstanding | 1.19% | 1.41% | 2.38% | 3.09% | 4.09% |
| Average Diluted Shares Outstanding | 6.90% | 9.63% | 7.89% | 6.03% | 9.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |